Rucaparib, which earned the FDA’s Breakthrough Therapy Designation in April 2015, is intended to treat patients with advanced ovarian cancer.
The agency’s priority review process was created to decrease the time it takes to put promising new medicines on the market. The FDA expects to make a decision on the drugs approval by February 2017.
Upon news of the drug’s priority review status, shares of Boulder, Colo.–based Clovis jumped almost 30 percent to $23.40.
More articles on the drug market:
Pfizer to buy AstraZeneca’s antibiotics portfolio: 6 things to know
FDA: Drug companies abuse citizen petitions to block generic competition
EpiPen isn’t the only drug with a price hike: Insulin prices skyrocket
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
